Part I Supplementary Figures

Table 1. Biomarkers by tumor type, specimen, timing, and clinical implication. Tests in this matrix are not universally indicated. Order selectively when results will change staging, referral, surveillance, or systemic therapy. “Specimen” denotes preferred source (tissue = FFPE from primary, SLN, or metastasis; IHC panels on tissue; blood = serum/plasma for protein markers or ctDNA).